NCT03780010View on ClinicalTrials.gov

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

TRC105

Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | Biotech Hunter | Biotech Hunter